Herbsens Botanicals marketed kratom capsules and powders as unapproved drugs to treat opioid addiction and other conditions.
What happened
FDA reviewed herbsenskratom.com in May 2022 and FTC reviewed it in June 2022. They found the site took orders for kratom capsule and powder products and made claims that the products treat opioid addiction and withdrawal, pain, depression, diabetes, high blood pressure, and other conditions. FDA determined the products are unapproved new drugs.
What FDA found
The website claims kratom products treat or manage opioid addiction and withdrawal, pain, depression, diabetes, high blood pressure, and other conditions, making them drugs intended for disease treatment.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are 'new drugs' (not generally recognized as safe and effective for their claimed uses) under the FD&C Act.
FD&C Act section 201(p), 21 U.S.C. 321(p)The company introduced the kratom products into interstate commerce without FDA approval.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The company advertised kratom as treating or curing addiction without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. §§ 41–57
What FDA wants
FDA asks the company to notify FDA in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with documentation, or explain why it believes the products are not violations. FTC separately asks for notice within 15 working days of actions taken to address its advertising concerns.
Who should pay attention
- retailers and online sellers of kratom products
- companies making addiction, pain, or other disease claims for botanical products
- quality and regulatory teams that review website claims and product drug status
This is a summary. Read the original letter on fda.gov.